Jump to main content
Jump to site search
Access to RSC content Close the message box

Continue to access RSC content when you are not at your institution. Follow our step-by-step guide.


Issue 40, 2018
Previous Article Next Article

Iron oxide nanoparticles for targeted imaging of liver tumors with ultralow hepatotoxicity

Author affiliations

Abstract

Even though iron oxide (Fe3O4) nanoparticles are promising materials for magnetic resonance imaging (MRI) contrast agents, their biocompatibility and targeting efficacy still need to be improved. Herein, we modified glycyrrhetinic acid (GA) groups on Fe3O4 nanoparticles (Fe3O4@cGlu-GA) for liver tumor-targeted imaging. To evaluate the biocompatibility of these nanoparticles, we studied their cytotoxicity, hemolysis, and hepatotoxicity. We measured the uptake of Fe3O4@cGlu-GA nanoparticles in normal and liver tumor cells, then we investigated the specificity of Fe3O4@cGlu-GA nanoparticles in mouse models bearing subcutaneous and orthotopic liver tumors. With good biocompatibility and targeting efficacy both in vitro and in vivo, the Fe3O4@cGlu-GA nanoparticles are promising MRI contrast agents with ultralow hepatotoxicity and show great improvement on existing Fe3O4-based nanoparticles.

Graphical abstract: Iron oxide nanoparticles for targeted imaging of liver tumors with ultralow hepatotoxicity

Back to tab navigation

Supplementary files

Article information


Submitted
24 Jun 2018
Accepted
03 Sep 2018
First published
06 Sep 2018

J. Mater. Chem. B, 2018,6, 6413-6423
Article type
Paper

Iron oxide nanoparticles for targeted imaging of liver tumors with ultralow hepatotoxicity

J. Li, R. Cha, Y. Zhang, H. Guo, K. Long, P. Gao, X. Wang, F. Zhou and X. Jiang, J. Mater. Chem. B, 2018, 6, 6413
DOI: 10.1039/C8TB01657G

Social activity

Search articles by author

Spotlight

Advertisements